Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune outcomes of lung transplant recipients with different cytochrome P450 3A5 phenotypes after discontinuation of voriconazole antifungal prophylaxis.

Clinical transplantation - 1 Jan 2024

Tu Zoe H, Pierce Brett J, Pasley Taylor, Hutchins Aaron, Huang Howard

Abstract excerpt

INTRODUCTION: Tacrolimus forms the backbone of immunosuppression regimens in lung transplant recipients (LTRs). It is extensively metabolized by cytochrome P450 (CYP) 3A5 enzymes, of which polymorphisms can significantly affect tacrolimus dose requirements. It is unknown how coadministration of tacrolimus with voriconazole, a potent CYP3A5 inhibitor, affects rejection rates or empiric dose adjustments needed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Immunosuppressive Agents

Share to Tacrolimus

Share to Transplant Recipients

Share to Voriconazole

Source

Identifiers

PMID: 38289893
DOI: 10.1111/ctr.15235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune outcomes of lung transplant recipients with different cytochrome P450 3A5 phenotypes after discontinuation of voriconazole antifungal prophylaxis.PMID 38289893Read ↗

Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients.Semantic proximity Read ↗

The impact of cytochrome P450 3A5 genotype on early tacrolimus metabolism and clinical outcomes in lung transplant recipients.Semantic proximity Read ↗

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.Semantic proximity Read ↗

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.Semantic proximity Read ↗

Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients.Semantic proximity Read ↗

The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.Semantic proximity Read ↗

Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients.Semantic proximity Read ↗

Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.Semantic proximity Read ↗

Effect of <em>CYP3A5</em> Polymorphism on Liver Function and Tacrolimus Pharmacokinetics after Conversion to a Once-Daily Tacrolimus Formulation in Stable Liver Transplant PatientsSemantic proximity Read ↗

Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.Semantic proximity Read ↗

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.Semantic proximity Read ↗

Phenotype of immunosuppression reduction after kidney transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.